Loading...
Loading...
PULM| Name | Value |
|---|---|
| Revenues | 1,708.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 1,708.0K |
| Operating Expense | 6,033.0K |
| Operating I/L | -4,325.0K |
| Other Income/Expense | 109.0K |
| Interest Income | 191.0K |
| Pretax | -4,216.0K |
| Income Tax Expense | -109.0K |
| Net Income/Loss | -4,107.0K |
Pulmatrix, Inc. is a clinical stage biotechnology company in the United States, specializing in inhaled therapies for respiratory and other diseases. The company's iSPERSE technology allows for the delivery of small or large molecule drugs to the lungs for local or systemic applications. Its product pipeline includes Pulmazole, an inhaled anti-fungal drug for allergic bronchopulmonary aspergillosis and cystic fibrosis patients; PUR1800, a kinase inhibitor in Phase 1b trials for chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation for acute migraine treatment. Pulmatrix has license and collaboration agreements with RespiVert Ltd., Cipla Technologies LLC, and Sensory Cloud, Inc.
